News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Another Biosimilar Legislative Defeat for Amgen (AMGN) & Genentech (RHHBY)


5/7/2013 7:47:32 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Once again, a state legislature has defeated a controversial push by some of the largest biotechs to establish new requirements for biosimilar substitution. The latest vote took place late last week in Florida, where the legislature approved a bill that follows current substitution practices for prescription medicines, rather than a measure that would have created new barriers to substitution. The outcome is a defeat for Amgen (AMGN) and Genentech, which have been lobbying more than a dozen states in hopes of thwarting rivals from having easy entre to their lucrative markets. As noted previously, the bills propose that a biosimilar must have been deemed by the FDA to be interchangeable with the prescribed medicine for the specified indicated use, even though the FDA has not yet approved a biosimilar or decided whether a biosimilar is interchangeable with a brand-name biologic.

Help employers find you! Check out all the jobs and post your resume.

Read at PharmaLive

comments powered by Disqus
Genentech
Amgen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES